tbuckley/cabot-search huggingface dataset:
Epidemiology of Tuberculosis and Progress Toward Meeting Global Targets — Worldwide, 2019
Authors: Rena Fukunaga, Philippe Glaziou, Jennifer B. Harris, Anand Date, Katherine Floyd, Tereza Kasaeva
Journal: MMWR Morbidity and Mortality Weekly Report (2021)

Although tuberculosis (TB) is curable and preventable, in 2019, TB remained the leading cause of death from a single infectious agent worldwide and the leading cause of death among persons living with HIV infection (1). The World Health Organization's (WHO's) End TB Strategy set ambitious targets for 2020, including a 20% reduction in TB incidence and a 35% reduction in the number of TB deaths compared with 2015, as well as zero TB-affected households facing catastrophic costs (defined as costs exceeding 20% of annual household income) (2). In addition, during the 2018 United Nations High-Level Meeting on TB (UNHLM-TB), all member states committed to setting 2018-2022 targets that included provision of TB treatment to 40 million persons and TB preventive treatment (TPT) to 30 million persons, including 6 million persons living with HIV infection and 24 million household contacts of patients with confirmed TB (4 million aged <5 years and 20 million aged ≥5 years) (3,4). Annual data reported to WHO by 215 countries and territories, supplemented by surveys assessing TB prevalence and patient costs in some countries, were used to estimate TB incidence, the number of persons accessing TB curative and preventive treatment, and the percentage of TB-affected households facing catastrophic costs (1). Globally, TB illness developed in an estimated 10 million persons in 2019, representing a decline in incidence of 2.3% from 2018 and 9% since 2015. An estimated 1.4 million TB-related deaths occurred, a decline of 7% from 2018 and 14% since 2015. Although progress has been made, the world is not on track to achieve the 2020 End TB Strategy incidence and mortality targets (1). Efforts to expand access to TB curative and preventive treatment need to be substantially amplified for UNHLM-TB 2022 targets to be met.
LOW BLOOD PRESSURE AND THE RISK OF DEATH AND STROKE IN CONTEMPORARY LEFT VENTRICULAR ASSIST DEVICE RECIPIENTS
Authors: Himabindu Vidula, Onur Altintas, Scott McNitt, Bronislava Polonsky, Jeffrey D. Alexis, Leway Chen, Igor Gosev, John D. Bisognano, Avi Seidmann, Ilan Goldenberg
Journal: Journal of the American College of Cardiology (2020)
Final results of a phase I and pharmacokinetic study of STEALTH liposomal CKD-602 (S-CKD602) in patients with advanced solid tumors
Authors: W. C. Zamboni, D. M. Friedland, S. Ramalingam, R. P. Edwards, R. G. Stoller, C. P. Belani, S. Strychor, Y. C. Ou, M. E. Tonda, R. K. Ramanathan
Journal: Journal of Clinical Oncology (2006)

2013 Background: S-CKD602 is a pegylated STEALTH liposomal formulation of CKD-602, a semi-synthetic analogue of camptothecin (CPT) and topoisomerase I inhibitor. Preclinical studies have shown that prolonged exposure to CPT achieves the greatest antitumor activity. STEALTH liposomes prolong the circulation time in plasma, achieve high and extended drug exposure in tumor, and provide a convenient dosing schedule. Methods: Patients (pts) were administered S-CKD602 IV over 1 h once every 3 wks. Modified Fibonacci escalation was used (3–6 pts/cohort), and dose levels ranged from 0.1–2.5 mg/m 2 . Serial plasma samples were obtained prior to administration to 96 h after administration, and on days 8 and 15 of cycle 1. Plasma samples were processed to measure concentrations of encapsulated (E), released (R), and sum total (E+R) CKD602 total (lactone + hydroxyl acid) by LC-MS/MS. Area under the plasma conc versus time curve (AUC 0- ∞ ) and t 1/2 were estimated. Results: 45 pts (21 male) have been treated: median age 62 y (range: 33–79 y); ECOG status: 0 and 1 (43 pts), 2 (2 pts). The majority of reported adverse events were grade (G) 1 and 2. Frequent nonhematological toxicities were asthenia, nausea, diarrhea, vomiting, and anorexia. Dose-limiting toxicities of G3 mucositis occurred in 1/6 pts at 0.3 mg/m 2 , G3/4 bone marrow suppression in 2/3 pts at 2.5 mg/m 2 , and G3 febrile neutropenia in 1/6 pts at 2.1 mg/m 2 . The maximum tolerated dose was 2.1 mg/m 2 . Stable disease for ≥ 6 cycles occurred in 5 pts (hepatocellular carcinoma (CA), thyroid, prostate, 2 pts sarcoma). Partial responses occurred in 2 pts with ovarian CA (1.7 and 2.1 mg/m 2 ). At 2.1 mg/m 2 , the mean ± SD AUC and t 1/2 of sum total S-CKD602 were 44 ± 33 μg/mL·h and 18 ± 8 h, respectively. In all plasma samples, &gt;90% of drug was encapsulated. Conclusions: S-CKD602 represents a promising new STEALTH liposomal CPT agent with manageable toxicity and promising antitumor activity. Phase II studies of S-CKD602 at 2.1 mg/m 2 IV once every 3 wks are planned. Prolonged plasma exposure over 1 to 2 wks is consistent with STEALTH liposomes and provides extended exposure compared with non-liposomal CPT. (Supported by ALZA and NIH/NCCR/GCRC #5M01 RR 00056). [Table: see text]
Anti-CCR4 Monoclonal Antibody, Mogamulizumab, Demonstrates Significant Improvement in PFS Compared to Vorinostat in Patients with Previously Treated Cutaneous T-Cell Lymphoma (CTCL): Results from the Phase III MAVORIC Study
Authors: Youn H. Kim, Martine Bagot, Lauren Pinter-Brown, Alain H. Rook, Pierluigi Porcu, Steven M. Horwitz, Sean Whittaker, Yoshiki Tokura, Maarten Vermeer, Pier Luigi Zinzani, Lubomir Sokol, Stephen Morris, Ellen Kim, Pablo L. Ortiz-Romero, Herbert Eradat, Julia Scarisbrick, Athanasios Tsianakas, Craig Elmets, Stephane Dalle, David C. Fisher, Ahmad S. Halwani, Brian Poligone, John P. Greer, Maria Teresa Fierro, Amit Khot, Alison J. Moskowitz, Karen Dwyer, Junji Moriya, Jeffrey Humphrey, Stacie Hudgens, Dmitri O. Grebennik, Kensei Tobinai, Madeline Duvic
Journal: Blood (2017)
PREVALENCE AND CHARACTERISTICS OF WILD TYPE TRANSTHYRETIN AMYLOID CARDIOMYOPATHY IN HOSPITALIZED PATIENTS REFERRED FOR TC-99M PYROPHOSPHATE (PYP) SCAN
Authors: Syed Bukhari, Amy Brownell, Ricardo Nieves, Yvonne S. Eisele, William Follansbee, Prem Soman
Journal: Journal of the American College of Cardiology (2020)
Phase I, multicenter trial of CNTO 328, an anti-interleukin(IL)-6 monoclonal antibody (mAb) in subjects with selected hematologic malignancies
Authors: R. Kurzrock, P. Voorhees, L. Fayad, R. Orlowski, F. Van Rhee, R. Furman, H. Borghaei, M. H. Zaki, U. Prabhakar, C. Garay
Journal: Journal of Clinical Oncology (2006)

2513 Background: IL-6 is implicated in the pathophysiology of several malignant diseases, including multiple myeloma (MM) and other hematological malignancies. CNTO 328 is a chimeric monoclonal antibody (mAb) that specifically binds and neutralizes human IL-6 with high affinity. A phase I trial is being conducted to assess safety and pharmacokinetics (PK) of CNTO 328 in subjects with B-cell non-Hodgkin’s lymphoma (NHL), MM, or Castleman’s Disease (CD). Methods: This trial will enroll at least 6 patients (pts) onto each of 5 cohorts, with 3 pts having a baseline C-reactive protein (CRP) of &lt;10 mg/L, and 3 with ≥10 mg/L. Dose limiting toxicity (DLT) is defined as a ≥ Grade 3 event (excluding hematologic toxicity), or ≥Grade 2 allergic reaction/hypersensitivity attributed to CNTO 328 after the first administration. Results: Results from the first 13 subjects (3 CD, 3 MM and 7 NHL) enrolled in Cohorts 1 and 2 are currently available. Pts have received a median number of 4 (range 2 to 12) intravenous doses. CNTO 328 alone was well tolerated without pre-medication, and no DLTs have been observed. Some grade 3 or 4 adverse events (AEs) such as nausea, vomiting, elevated triglycerides, and decreased neutrophils were observed. Two subjects experienced serious AEs (SAEs) that were deemed unrelated to CNTO 328. Each of 3 pts with CD showed a clinical response, including improvement of hemoglobin, reduction of fever, resolution of rash, or decrease in lymphadenopathy. In one case of mantle cell NHL there was a reduction in lymphadenopathy. Two of 4 pts with previously progressive MM showed stabilization of M-protein levels and in % plasma cells in the bone marrow after one cycle of therapy. PK data is being analyzed. Conclusions: Treatment with CNTO 328 has been well tolerated at doses up to 6 mg/kg q 2 weeks. No clinical immune reaction to this chimeric mAb has been observed, and early evidence of tumor response and disease control has been observed. [Table: see text]
Influence of hospital characteristics on immediate breast reconstruction following mastectomy.
Authors: Catherine A. Richards, Jason Dennis Wright, Alfred I. Neugut, Jeffrey Ascherman, Dawn L. Hershman
Journal: Journal of Clinical Oncology (2012)

6118 Background: Immediate breast reconstruction (IBR) following mastectomy is underutilized in the U.S. Racial, economic and geographic factors are associated with lower rates of IBR. Prior research has explored the association of individual and surgeon-level factors with the use of IBR, with little attention paid to hospital characteristics. Methods: We analyzed data from the 2008 Nationwide Inpatient Sample (NIS), a 20% random sample of academic, public and private U.S. hospitals. We used ICD-9 codes to identify women diagnosed with invasive breast cancer or DCIS who underwent mastectomy, and IBR (natural or expander/implant). If a hospital performed at least one IBR during 2008, they were classified as performing reconstruction. Relative risk regression was used to assess the hospital factors associated with a hospital performing IBR. Results: Of the 3,518 hospitals that performed mastectomy in 2008 only 50.4% performed at least one IBR. For hospitals that did not perform IBR, the average number of mastectomies was 5, compared to 35 at hospitals that did perform IBR (p&lt;0.01). Among hospitals that did perform IBR, the mean proportion of mastectomy patients that had IBR was 34% (SD=20). In a multivariable adjusted model, urban/teaching (RR=3.47) and urban/non-teaching (RR=2.86) hospitals were significantly more likely to perform IBR compared to rural hospitals. Hospitals with a high proportion of privately insured patients (RR=1.10) were significantly more likely to perform IBR compared to hospitals with a low proportion of privately insured patients. In contrast, hospitals with a high proportion of publically insured patients (RR=0.24) and hospitals with a high proportion of female patients ≥ 70 years old (RR=0.75) were significantly less likely to perform IBR. Hospital region, hospital ownership status and the proportion of nonwhite patients were not significantly associated with IBR. Conclusions: Almost half of all U.S. hospitals where mastectomies are performed do not have any patients who have undergone IBR. The likelihood a hospital will perform IBR varies significantly by hospital characteristics.
Nusinersen in adults with 5q spinal muscular atrophy: a non-interventional, multicentre, observational cohort study
Authors: Tim Hagenacker, Claudia D Wurster, René Günther, Olivia Schreiber-Katz, Alma Osmanovic, Susanne Petri, Markus Weiler, Andreas Ziegler, Josua Kuttler, Jan C Koch, Ilka Schneider, Gilbert Wunderlich, Natalie Schloss, Helmar C Lehmann, Isabell Cordts, Marcus Deschauer, Paul Lingor, Christoph Kamm, Benjamin Stolte, Lena Pietruck, Andreas Totzeck, Kathrin Kizina, Christoph Mönninghoff, Otgonzul von Velsen, Claudia Ose, Heinz Reichmann, Michael Forsting, Astrid Pechmann, Janbernd Kirschner, Albert C Ludolph, Andreas Hermann, Christoph Kleinschnitz
Journal: The Lancet Neurology (2020)
Surgery of colorectal metastasis in the Optimox 1 study. A GERCOR Study
Authors: N. Perez-Staub, G. Lledo, F. Paye, B. Gayet, M. Flesch, A. Cervantes, A. Figer, O. Bourges, T. André, A. De Gramont
Journal: Journal of Clinical Oncology (2006)

3522 Background: Surgery of metastasis can cure arround 20% of metastatic colorectal cancer (MCRC) patients. The Optimox 1 study achieved a response rate over 50% with FOLFOX therapy in patients (pts) with initially unresectable metastasis which allowed to perform surgery in a significant number of pts (JCO 2006). We report here the results in pts who underwent surgery of metastasis (met). Methods: From jan 2000 to june 2002, 620 previously untreated patients with unresectable metastasis were randomized between FOLFOX4 every two weeks until progression (arm A), or FOLFOX7 for 6 cycles, maintenance without oxaliplatin for 12 cycles and reintroduction of FOLFOX7 (arm B). 101 pts were resected with a curative intent, 57 in arm A and 45 in arm B. Results: Patients characteristics were (arm A/B %): metachronous metastasis 77/51, liver met 82/91, lung met 16/11, other met 7/4, PAL &lt; 3 ULN: 98/97, normal LDH: 52/51. 8% of pts achieved a complete response, 72% a partial response, 16% a stable disease. 89 pts had a single resection, 12 had a two-stage surgery. One patient died in arm B. Eleven pts who relapsed had a second surgery. Resection was radical (R0) for 71 pts (43 in arm A and 28 in arm B), 15 were R1 (margin invasion) and 15 were R2. R0/R1 patients had a median overall survival (OS) of 51 mo in arm A and 38 mo in arm B. Median disease-free survival (DFS) since surgery was 12 mo in arm A and 9 mo in arm B, with no statistical difference. 32% of R0/R1 pts were alive with no progression at 3 years in arm A and 20% in arm B. Median time from randomization to surgery was 8 mo. No difference was found between patients resected before 8 mo (n = 50) and after (n = 37) in OS (39 vs 45 mo, p = .67) nor in DFS (11.6 vs 9.5 mo, p = .24). Neither in pts resected before and after 6 mo in OS (p = .77) and DFS (p = .44). Conclusions: FOLFOX treatment allowed 14 % of unresectable patients to be rescued by surgery. There was no additional benefit to perform surgery after 6 months of therapy compared to early surgery. [Table: see text]
IMPACT OF BALLOON PULMONARY ANGIOPLASTY ON RIGHT VENTRICULAR FUNCTION FOR CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION
Authors: Keiko Sumimoto, Hidekazu Tanaka, Jun Mukai, Kentaro Yamashita, Yusuke Tanaka, Ayu Shono, Makiko Suzuki, Shun Yokota, Makiko Suto, Hiroki Takada, Kensuke Matsumoto, Yu Taniguchi, Noriaki Emoto, Ken-Ichi Hirata
Journal: Journal of the American College of Cardiology (2020)
Targeting MYCN-expressing triple-negative breast cancer with BET and MEK inhibitors
Authors: Johanna M. Schafer, Brian D. Lehmann, Paula I. Gonzalez-Ericsson, Clayton B. Marshall, J. Scott Beeler, Lindsay N. Redman, Hailing Jin, Violeta Sanchez, Matthew C. Stubbs, Peggy Scherle, Kimberly N. Johnson, Quanhu Sheng, Joseph T. Roland, Joshua A. Bauer, Yu Shyr, Bapsi Chakravarthy, Bret C. Mobley, Scott W. Hiebert, Justin M. Balko, Melinda E. Sanders, Phillip C. C. Liu, Jennifer A. Pietenpol
Journal: Science Translational Medicine (2020)

This study demonstrates the potential utility of BET and MEK inhibitors for advanced MYCN-expressing triple-negative breast cancer.
HSR20-100: Results From a Pilot Study Examining the Impact of Distress Screening and Referral on Cancer Patient Cost and Health Care Utilization
Authors: Melissa F. Miller, Melyssa Allen, Diane Robinson, Nicole Nicksic, Alexandra Zaleta
Journal: Journal of the National Comprehensive Cancer Network (2020)

"HSR20-100: Results From a Pilot Study Examining the Impact of Distress Screening and Referral on Cancer Patient Cost and Health Care Utilization" published on 20 Mar 2020 by National Comprehensive Cancer Network.
The impact of sarcopenia on transplant-related complications and number of days spent in the hospital in patients with lymphoma.
Authors: Megan Veresh Caram, Daniel R. Couriel, Jennifer J. Griggs, Emily Light Bellile, Michael Englesbe
Journal: Journal of Clinical Oncology (2013)

7044 Background: Sarcopenia, a state of abnormally low muscle mass, has been found to be associated with more treatment-related complications and shorter overall survival in patients with different cancers. Sarcopenia can be reliably assessed with routine computerized tomography (CT). The objectives of the study were to determine whether sarcopenia is associated with the number of complications and the number of days spent in the hospital in patients undergoing autologous hematopoietic stem cell transplantation (autoSCT) for lymphoma. Methods: Adult patients treated for non-Hodgkin's or Hodgkin's lymphoma with autoSCT between 2/2005 – 6/2/2012 at the University of Michigan (U-M) Bone Marrow Transplant (BMT) Program were eligible for inclusion if a CT of the abdomen was performed within 60 days prior to autoSCT. Total psoas area and lean psoas area were calculated for each patient with cross-sectional area and density measurements taken at the level of the fourth lumbar vertebra using algorithms programmed in the Analytic Morphomics Lab at U-M. All analyses were completed using Poisson regression models controlling for age, gender, body mass index, Hematopoeitic-Cell Transplant Co-morbidity Index (HCT-CI), and Karnofsky performance status (KPS). Results: Total and lean psoas area were calculated in the 121 patients who met inclusion criteria. Men with greater psoas muscle measures experienced fewer complications and spent fewer days in the hospital during the autoSCT admission compared to men who were sarcopenic (complications β = -0.206, p=0.001; hospital treatment days β = -0.043, p=0.029). Sarcopenia did not play a role in outcomes in women. A strong association existed between sarcopenia and re-admission days within 100 days following autoSCT among both men (β = -1.183, p&lt;0.0001) and women (β = -0.805, p&lt;0.0001). Conclusions: Muscle mass is independently associated with complication rates and duration of hospitalization in patients undergoing autoSCT for lymphoma. CT-determined psoas muscle mass may be a valuable addition to other indices used to guide optimal treatment selection and serve as a potentially modifiable host factor to improve transplant-related outcomes.
Association of Afamelanotide With Improved Outcomes in Patients With Erythropoietic Protoporphyria in Clinical Practice
Authors: Debby Wensink, Margreet A. E. M. Wagenmakers, Jasmin Barman-Aksözen, Edith C. H. Friesema, J. H. Paul Wilson, Joost van Rosmalen, Janneke G. Langendonk
Journal: JAMA Dermatology (2020)

<h3>Importance</h3> The effectiveness of afamelanotide treatment in patients with erythropoietic protoporphyria (EPP) in clinical practice who experience pain after light exposure that substantially impairs quality of life is unknown. <h3>Objective</h3> To evaluate the association of afamelanotide treatment with outcomes in patients with EPP in regular practice during longer-term follow-up. <h3>Design, Setting, and Participants</h3> This single-center, prospective postauthorization safety and efficacy cohort study was directed and approved by the European Medicines Agency. Data were collected from patients with EPP treated with afamelanotide at Erasmus MC between June 2016 and September 2018. Analysis began October 2018. <h3>Main Outcomes and Measures</h3> Time spent outside during treatment, number of phototoxic reactions, disease-specific quality of life, usage of protective clothing, and adverse events. <h3>Results</h3> A total of 117 patients with EPP (59 women [50.4%]; mean [SD] age, 43.0 [15.5] years) were treated with afamelanotide. Nearly all patients continued treatment (115 [98%]) with a median (interquartile range) follow-up of 2.0 (1.3-2.1) years. Compared with baseline, mean time spent outside during treatment increased significantly by an added 6.1 hours per week (95% CI, 3.62-8.67;<i>P</i> &lt; .001). Mean quality of life score improved significantly by 14.01% (95% CI, 4.53%-23.50%;<i>P</i> &lt; .001). Phototoxic reactions were less painful (β, −0.85; 95% CI, −1.43 to −0.26;<i>P</i> &lt; .001), but there was no significant difference in number or duration of reactions. Minor self-limiting adverse events occurred, such as nausea, fatigue, and headache. <h3>Conclusions and Relevance</h3> This cohort study found that afamelanotide treatment was associated with improved clinical outcomes and a good safety profile for patients with EPP. The treatment has clinically significant, sustained positive associations with quality of life, is associated with increased duration of sun exposure, and is associated with less severe phototoxic reactions.
Concomitant chemoradiotherapy with orally used agents in locally advanced gastric carcinoma: Two years results
Authors: M. H. Akboru, S. T. Dincer, A. Yoney, B. Askaroglu, M. Unsal
Journal: Journal of Clinical Oncology (2006)

14127 Background: We designed a prospective study to evaluate tolerability, toxicity and effectiveness of concomitant chemoradiotherapy with oral tegafur-uracil (UFT) and leucovorin in locally advanced gastric carcinoma. 13 patients admitted to our center in 10 months of 2003 (March– December) were included. Methods: Only one of the patients was female (7.7%). Median age was 52 (34–72). All of them were operated with negative surgical margins (53.8% of them have undergone total gastrectomy and rest of them were operated subtotally). All of them have 0 and 1 performance status (ECOG). Their tumor were mostly located in antrum (53.8%). 4 (30.8%) of them in stage II and in stage IIIA, IIIB and IV were as follows: 2 (15.4%), 5 (38.5%) and 2 (15.4%). Median lymph node dissection was 14 (7–31). Median time interval between surgery and treatment was 49 days (25–63). All patients were treated 45 Gy (one patient 39.6 Gy and other patient 50.4 Gy) locoregional radiotherapy (RT) and UFT 300 mg/m 2 /day + leucovorin 90 mg/day in three times a day during RT. Results: All patients tolerated therapy well (RT was interrupted 3 times just in one patient because of grade III emesis). At the end of median two years follow up; recurrence was seen as metastasis in 4 (30.8%) patients and locoregional in 3 (23.1%). 8 patients (61.5%) died (one of them was not related). Median progression free survival was 17 months (6–34) with 53.8% in one year and 38.5% in two years. Median overall survival (OS) was 24 months (8–34), one and two years OS were 76.9% and 46.2%, respectively. Conclusions: Concomitant chemoradiotherapy with orally used agent (UFT and leucovorin) in locally advanced gastric carcinoma is well tolerated regimen. But to increase survival data by continuing therapy with these agent after chemoradiotherapy must be researched. To answer this question another study was conducted and is going on in our center. No significant financial relationships to disclose.